Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy; D002214:Capsules / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000628:therapy; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D015282:Octreotide / Q000031:analogs & derivatives*; D010190:Pancreatic Neoplasms / Q000628:therapy; D011471:Prostatic Neoplasms / Q000628:therapy; D051381:Rats; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017329:Triptorelin Pamoate
D000970:Antineoplastic Agents; D002214:Capsules; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013004:Somatostatin; C053408:RC 121; D015282:Octreotide